Stocks of Sarepta Therapeutics Inc (NASDAQ:SRPT) traded higher last session on Wall Street, up 13.68% to $76.52.
According to the data, Sarepta Therapeutics Inc (NASDAQ:SRPT) has 19 analysts covering its stock. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $220.00 and a low of $40.00, we find $146.00. Given the previous closing price of $67.31, this indicates a potential upside of 116.91 percent. SRPT stock price is now -34.61% away from the 50-day moving average and -37.70% away from the 200-day moving average. The market capitalization of the company currently stands at $7.14B.
A total of 5 analysts have issued a hold rating and 12 have given it a buy rating. Brokers who have rated the stock have averaged $140.00 as their price target over the next twelve months.
In other news, Chambers Michael Andrew, Director bought 9,979 shares of the company’s stock on Aug 14. The stock was bought for $1,092,429 at an average price of $109.47. Upon completion of the transaction, the Director now directly owns 246,996 shares in the company, valued at $18.9 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 11, Director Chambers Michael Andrew bought 23,686 shares of the business’s stock. A total of $2,559,272 was incurred on buying the stock at an average price of $108.05. This leaves the insider owning 237,017 shares of the company worth $18.14 million. Insiders disposed of 28,587 shares of company stock worth roughly $2.19 million over the past 1 year. A total of 5.69% of the company’s stock is owned by insiders.
Wednesday’s opening bell rang with an opening price of $57.63 for Sarepta Therapeutics Inc (NASDAQ: SRPT). During the past 12 months, Sarepta Therapeutics Inc has had a low of $55.25 and a high of $159.89. As of last week, the company has a debt-to-equity ratio of 1.84, a current ratio of 4.96, and a quick ratio of 4.50. The fifty day moving average price for SRPT is $117.02 and a two-hundred day moving average price translates $122.79 for the stock.
The latest earnings results from Sarepta Therapeutics Inc (NASDAQ: SRPT) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.27, beating analysts’ expectations of -$1.78 by 1.51. This compares to -$2.65 EPS in the same period last year. The net profit margin was -90.46% and return on equity was -123.67% for SRPT. The company reported revenue of $261.24 million for the quarter, compared to $233.49 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 11.89 percent. For the current quarter, analysts expect SRPT to generate $288.5M in revenue.
